Widely used:Recently Viewed
Clear All
$1,153 Mln
--
2.75
--
0
-50.63 %
--
--
--
-11121659
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Praxis Precision Medicines Inc (PRAX)
| 190.71 | 19.90 | 60.64 | 182.22 | -39.20 | -- | -- |
|
BSE Sensex
| 13.00 | 0.56 | 2.05 | 23.70 | 11.01 | 16.81 | 12.01 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Praxis Precision Medicines Inc (PRAX)
| -37.59 | -87.92 | -64.19 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$1,153.15 Mln
$1.77 Mln
$0.00 Mln
$351.88 Mln
$1.95 Mln
High
$13.01 - 283.50
17,757,100
NASDAQ: PRAX
Boston, MA
https://praxismedicines.com
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a... small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. Address: 99 High Street, Boston, MA, United States, 02110 Read more
The total asset value of Praxis Precision Medicines Inc (PRAX) stood at $ 462 Mln as on 30-Jun-24
The share price of Praxis Precision Medicines Inc (PRAX) is $64.77 (NASDAQ) as of 08-Oct-2024 16:00 EDT. Praxis Precision Medicines Inc (PRAX) has given a return of -39.2% in the last 3 years.
Praxis Precision Medicines Inc (PRAX) has a market capitalisation of $ 1,153 Mln as on 07-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Praxis Precision Medicines Inc (PRAX) is 2.75 times as on 07-Oct-2024, a 12% discount to its peers’ median range of 3.14 times.
Since, TTM earnings of Praxis Precision Medicines Inc (PRAX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Praxis Precision Medicines Inc (PRAX) and enter the required number of quantities and click on buy to purchase the shares of Praxis Precision Medicines Inc (PRAX).
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. Address: 99 High Street, Boston, MA, United States, 02110
The CEO & director of Mr. Marcio Silva De'Souza M.B.A.. is Praxis Precision Medicines Inc (PRAX), and CFO & Sr. VP is Mr. Marcio Silva De'Souza M.B.A..
There is no promoter pledging in Praxis Precision Medicines Inc (PRAX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Praxis Precision Medicines Inc (PRAX) | Ratios |
|---|---|
|
Return on equity(%)
|
-50.63
|
|
Operating margin(%)
|
-7523.21
|
|
Net Margin(%)
|
-6987.01
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Praxis Precision Medicines Inc (PRAX) was $0 Mln.
$2.28
